





Figure 1



* Either study provided commercially available dapagliflozin 10mg QD or continue regularly prescribed SGLT2i
**End of Study: Subjects who do not participate in the OLE, will attend a 2week End of Study Safety Follow-up visit.

Abbreviations: OLE, open label extension; QD, once daily; SGLT2i, sodium glucose cotransporter 2 inhibitor

Figure 2